A recent study reveals comparable outcomes for radical cystectomy and bladder-sparing therapy in treating recurrent ...

Research on myeloma shows significant progress in treatment options, emphasizing the need for early detection and access to ...

Giredestrant shows lower treatment discontinuation rates compared to standard therapy and is being explored in combination ...

The Garden of Hope provides cancer survivors with access to fresh produce and a supportive community, bridging clinical ...

Key FDA action dates in early 2026 promise to transform treatment options for solid tumors and rare hematologic malignancies, ...

Heather Cooper Ortner leads the International Myeloma Foundation, focusing on advancing research, improving patient access, and enhancing support for myeloma care. The International Myeloma Foundation ...

In July, the FDA issued a complete response letter (CRL) for Replimune's biologics license application for RP1 (vusolimogene ...

For centuries, the field of pathology has been defined by a single instrument: the microscope. But according to William ...

On August 8, 2025, the FDA granted accelerated approval to zongertinib for adult patients with unresectable or metastatic ...

While the current approval focuses on the second-line setting, research is already moving into earlier stages of the ...

Discover the latest breakthroughs in multiple myeloma treatment, including CAR T-cell therapies and promising new options for ...

The US FDA has approved mosunetuzumab-axgb (Lunsumio VELO) as a subcutaneous formulation for the treatment of adult patients ...